Accessibility Menu
PharmaCyte Biotech logo

PharmaCyte Biotech

(NASDAQ) PMCB

Current Price$0.67
Market Cap$7.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-100%
5 Year-95%
1 Year-41%
1 Month-20%
PharmaCyte Biotech last closing stock price
MetricPriceDate
Last closeUSD 0.662026-07-16
PharmaCyte Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.74%USD 0.702026-07-09
1 month-20.31%USD 0.832026-06-16
3 month-9.44%USD 0.732026-04-17
Year to date-8.87%USD 0.722025-12-31
1 year-41.09%USD 1.122025-07-16
3 year-76.93%USD 2.862023-07-17
5 year-94.96%USD 13.102021-07-16
Since inception-99.71%USD 224.992003-09-11

PharmaCyte Biotech Financials at a Glance

Market Cap

$7.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$3.28M

EPS (TTM)

-$1.04

P/E Ratio

-0.63

Dividend

$0.00

Beta (Volatility)

0.52 (Low)

Price

$0.67

Volume

75,281.518

Open

$0.63

Previous Close

$0.66

Daily Range

$0.63 - $0.68

52-Week Range

$0.63 - $1.51

Estimated Earnings Date

Jul 1, 2026

PMCB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PharmaCyte Biotech

PharmaCyte develops cell-based therapies for cancer. Its treatments aim to help patients with hard-to-treat diseases. The company uses encapsulated living cells to deliver targeted therapy inside the body.

Therapies in a Capsule: What PharmaCyte Offers

  • Cell-in-a-Box platform: Encapsulates live, engineered cells for targeted drug delivery; 0% of revenue (pre-revenue).
  • CypCaps: Therapy candidate for advanced pancreatic cancer using encapsulated cells; 0% of revenue.
  • Diabetes therapies: Previously investigated encapsulated insulin-producing cells for Type 1 and insulin-dependent Type 2 diabetes; 0% of revenue.
  • Cannabis-based therapies: Research on cannabis plant components for cancer treatment; 0% of revenue.

Growth Moves: PharmaCyte’s Strategic Steps

  • 2015: Changed name from Nuvilex to PharmaCyte to reflect new focus.
  • 2025: Raised $7 million through Series C preferred stock and warrants.
  • 2025: Invested $3 million in QCLS Series H Preferred Stock and warrants.
  • Ongoing: Research partnerships with University of Technology, Sydney and University of Northern Colorado.
  • Paused diabetes research to focus on cancer therapy development as of the year ended April 30, 2024.

Why PharmaCyte Stands Out (Without the Lab Coat)

PharmaCyte’s technology delivers live cells directly to disease sites, aiming for precise treatment. Its approach may reduce side effects by activating drugs only where needed. The company’s small team relies on academic and industry partners for research and manufacturing expertise.

Five Things You Need to Know

  • No revenue reported for the nine months ended January 31, 2026.
  • Net loss was $18.3 million for the same period, up from net income last year.
  • Operating expenses rose 30.2% year-over-year to $4.3 million in January 2026.
  • Cash and equivalents were $20.2 million as of January 31, 2026, up 32.9% from April 2025.

Bottom Line

PharmaCyte remains a pre-revenue biotech focused on cell-based therapies for cancer and diabetes. Its future depends on clinical progress, regulatory outcomes, and continued funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

Joshua Nathaniel Silverman

Website

pharmacyte.com

Headquarters

Las Vegas, NV 89169, US

PMCB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-7.68%

Return on Capital

-8.44%

Return on Assets

-5.87%

Earnings Yield

-1.59%

Dividend Yield

0.00%

Payout Ratio

-4.96%

Stock Overview

Market Cap

$7.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

10.74M

Volume

75.28K

Avg. Volume

172.12K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$5.38M

EBITDA

-$12.90M

Operating Cash Flow

-$4.80M

Capital Expenditure

$0.00

Free Cash Flow

-$4.80M

Cash & ST Invst.

$20.54M

Total Debt

$0.00

PharmaCyte Biotech Performance Analysis

PharmaCyte Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-04-30USD 0N/A
20232023-04-30USD 0N/A
20242024-04-30USD 0N/A
20252025-04-30USD 0N/A
PharmaCyte Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-04-30N/A
Q12025-07-31N/A
Q22025-10-31N/A
Q32026-01-31N/A
PharmaCyte Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-04-30USD -0.27N/A
20232023-04-30USD -0.22-18.9%
20242024-04-30USD -1.80712.2%
20252025-04-30USD 3.19N/A
PharmaCyte Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-04-30463.6%
Q12025-07-31-176.9%
Q22025-10-31-0.8%
Q32026-01-3186.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$7.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.54M

N/A

Employees

2

N/A

Net Income

$746.86K

+124.5%

EBITDA

-$2.12M

-120.6%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$20.54M

+22.6%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-5.87%

N/A

Return on Invested Capital

-9.94%

N/A

Free Cash Flow

-$786.85K

-54.3%

Operating Cash Flow

-$786.85K

-54.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QNRXQuoin Pharmaceuticals, Ltd.
$4.10-1.44%
RADXRadiopharm Theranostics Limited
$4.32+0.64%
TCRTAlaunos Therapeutics, Inc.
$2.02-2.42%
BCLIBrainstorm Cell Therapeutics Inc.
$0.91-3.45%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.12-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$69.42-0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$30.23+0.10%
PATHUiPath
$12.30+0.02%

Questions About PMCB

What is the current price of PharmaCyte Biotech?

PharmaCyte Biotech is trading at $0.64 per share.

What is the 52-week range for PharmaCyte Biotech?

Over the past 52 weeks, PharmaCyte Biotech has traded between $0.63 and $1.51.

How much debt does PharmaCyte Biotech have?

As of the most recent reporting period, PharmaCyte Biotech reported total debt of $0.00.

How much cash does PharmaCyte Biotech have on hand?

PharmaCyte Biotech reported $20.17M in cash and cash equivalents in its most recent financial results.

What is PharmaCyte Biotech’s dividend yield?

PharmaCyte Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services